Graphite Bio, Inc. (GRPH)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Graphite Bio, Inc. (GRPH)
Company Performance

Current Price

as of Oct 18, 2024

$27.99

P/E Ratio

N/A

Market Cap

$723.42M

Description

Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA.

Metrics

Overview

  • HQSouth San Francisco, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerGRPH
  • Price$27.99+6.34%

Trading Information

  • Market Cap$723.42M
  • Float81.61%
  • Average Daily Volume (1m)161,966
  • Average Daily Volume (3m)146,396
  • EPS-$9.44

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$10.25M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$14.33M
  • EV$248.25M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B3.75
Documents
SEC Filings
8-K (2024-08-14)
8-K (2024-08-12)
8-K (2024-07-15)
8-K (2024-05-08)
8-K (2024-04-03)
8-K (2024-03-22)
8-K (2024-03-19)
8-K (2024-03-14)
8-K (2024-03-08)
8-K (2024-03-05)
8-K (2023-12-26)
8-K (2023-11-15)
8-K (2023-10-30)
8-K (2023-08-23)
8-K (2023-08-02)
8-K (2023-07-20)
8-K (2023-06-23)
8-K (2023-03-20)
8-K (2023-03-16)
8-K (2023-02-22)
8-K (2023-01-05)
10-Q (2024-08-14)
10-Q (2024-05-08)
10-Q (2023-11-13)
10-Q (2023-08-14)
10-Q (2023-05-11)
10-K (2024-02-27)
10-K (2023-03-20)
Factset
Factset Business Description
Factset Street Account
LENZ Therapeutics and Graphite Bio announce merger agreement ($2.33, 0.00) (2023-11-15T12:08:00Z)
Graphite Bio reports Q3 GAAP EPS ($0.39) vs year-ago ($0.45) - 10-Q ($2.30, 0.00) (2023-11-13T21:32:21Z)
Graphite Bio halted; news pending ($2.33, 0.00) (2023-11-15T11:59:16Z)
Wikipedia
Graphite_bomb